Clinical Trial Update: Study Evaluating Bifeprunox in Patients With Schizophrenia. [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating Bifeprunox in schizophrenia has been terminated. The sponsor Wyeth, now part of Pfizer, terminated the trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Bifeprunox (bifeprunox)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Schizophrenia | Phase 3 | Status: TERMINATED